Skip to main content
. 2022 May 3;13:2400. doi: 10.1038/s41467-022-30003-5

Fig. 2. HRR genes alterations (PROfound genes) are highly represented and the HRD signature is enriched in PCBM.

Fig. 2

a Comparison of HRD signature scores, estimated by SigMA for TCGA (n = 495), PCBM primary (n = 63), CRPC500 non-brain metastatic (n = 411), and PCBM metastatic (n = 105) samples (Wilcoxon test, two sided). Horizontal lines in boxplots show median, hinges show interquartile range, whiskers show 1.5 x interquartile range, points beyond 1.5 x IQR past hinge are shown. b Summary of mutations and copy number alterations affecting HR genes included in the PROfound clinical trial. Alterations (coding and copy number) are colored according to the legend. Ploidy annotation from FACETS and samples passing the HRD Signature ‘strict’ cutoff from SigMA are indicated. Source data are provided as a Source Data file.